I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Urokinase is used clinically as a thrombolytic agent in the treatment of severe or massive deep venous thrombosis, pulmonary embolism, myocardial infarction, and occluded intravenous or dialysis cannulas. It is also administered intrapleurally to improve the drainage of complicated pleural effusions and empyemas. Urokinase is a thrombolytic drug in infarction. Urokinase-plasminogen activator may be a new prognostic marker in breast cancer.
Michael J. Duffy,; Liam O'siorain M,; James J. Fennelly. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988, 62 (3),531-533,.
Stump DC,; Thienpont M,; Collen D.s. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex.. J Biol Chem. 1986, 261 (3), 1267-73.